Targeting the Mitochondria by Novel Adamantane-Containing 1,4-Dihydropyridine Compounds by Linda Klimaviciusa et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
11 
Targeting the Mitochondria by Novel 
Adamantane-Containing  
1,4-Dihydropyridine Compounds 
Linda Klimaviciusa1, Maria A. S. Fernandes2, Nelda Lencberga1,  
Marta Pavasare1, Joaquim A. F. Vicente2, António J. M. Moreno2,  
Maria S. Santos3, Catarina R. Oliveira4, Imanta Bruvere5,  
Egils Bisenieks5, Brigita Vigante5 and Vija Klusa1 
1Department of Pharmacology, Faculty of Medicine, University of Latvia, Riga 
2IMAR-CMA, Department of Life Sciences, University of Coimbra, Coimbra 
3CNC, Department of Life Sciences, University of Coimbra, Coimbra  
4CNC, Faculty of Medicine, University of Coimbra, Coimbra 
5Laboratory of Membrane Active and beta-Diketone Compounds,  
Latvian Institute of Organic Synthesis, Riga 
2,3,4Portugal 
1,5Latvia 
1. Introduction 
Mitochondria are important regulators of cellular functions and energy metabolism, 
therefore mitochondrial dysfunction leads to a compromised energy-generating system, 
deteriorated cellular homeostasis and neurodegenerative disorders, such as Parkinson’s 
disease and Alzheimer’s disease (Shapira, 1999; 2009). Hence, the protection of 
mitochondria, even their repair mechanisms at the level of complex I, may be a key strategy 
in limiting mitochondrial damage and ensuring cellular integrity (Dawson  Dawson, 2003). 
Thus, in addition to traditionally used antiparkinsonian drugs, which are focused on the 
activation of the dopaminergic system, different mitochondria-protecting agents are being 
used in clinics for the treatment of Parkinson’s disease. For instance, agents with antioxidant 
properties, such as melatonin (Esposito & Cuzzocrea, 2010), coenzyme Q10 and creatine 
(Kones, 2010), lipoic acid (De Araújo et al., 2011), and the extract of Hyoscyamus niger seeds 
(Sengupta et al., 2011), are currently used to treat Parkinson’s disease. 
Recently, antihypertensive drugs of the calcium antagonistic series, which belong to 1,4-
dihydropyridine (DHP) class and are capable of penetrating the blood-brain barrier (e.g., 
nifedipine, nimodipine), were shown to significantly reduce the risk of developing 
Parkinson’s disease (Becker et al., 2008; Ritz et al., 2010). This was explained by blocking L-
type calcium channels in the dopaminergic neurons of the substantia nigra, where elevated 
calcium ion concentrations initiate cell death (Sulzeret & Schmitz, 2007). However, the 
mechanism of the antiparkinsonian action of DHPs is not yet understood. 
Our investigation of DHP compounds showed that many of them are capable of protecting 
mitochondrial processes (Fernandes et al., 2003, 2005, 2008, 2009). For instance, the most 
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active compound cerebrocrast {4-[2-(difluoromethoxy)phenyl-2,6-dimethyl-1,4-
dihydropiridine-3,5-dicarboxylic acid di(2-propoxyethyl)diester}, which has shown 
neuroprotective effects in different neurodeficiency models (Klusa, 1995), decreased 
mitochondrial toxin 1-methyl-4-phenylpyridinium (MPP+)-induced cell death in rat 
cerebellar granule cells (Klimaviciusa et al., 2007). In isolated mitochondria of rat liver, 
cerebrocrast inhibited the inner mitochondrial anion channel, Ca2+-induced opening of the 
mitochondrial membrane permeability transition pore and permeabilization of the 
mitochondrial inner membrane (Vicente et al., 2006). In addition, it normalized oxidative 
phosphorylation and increased adenosine triphosphate (ATP)-induced contraction in 
swollen mitochondria of isolated rat skeletal muscle (Velena et al., 1997). Cerebrocrast and 
its congeners also protected against histopathological changes caused by azidothymidine, 
known to be a mitochondrial toxin (Pupure et al., 2008). 
The present study investigates two novel DHP compounds, cerebrocrast analogues 
containing structure elements that may enhance the delivery of molecules through the 
blood-brain barrier and improve their access to mitochondria. The compounds are 
composed of either one adamantane moiety in position 3 (AV-6-93) or two adamantane 
moieties in positions 3 and 5 (diflurone) of the DHP ring. We suggest that these DHP 
structures may possess mitochondria-protecting and antiparkinsonian activity due to both 
the adamantane moiety, which can be considered to be an important functional unit, and the 
DHP structure, which may serve as the carrier molecule. Adamantane molecules were 
previously used in the design of neuroprotective drugs. For example, amantadine (1-amino-
adamantane) is used in antiparkinsonian drugs with mechanisms focused on NMDA-
receptor gated ion channels (Kornhuber et al., 1991). Adamantane derivatives, particularly 
memantine, are reported as neuroprotective agents against mitochondrial toxicity in vivo 
(Rojas et al., 2008) and in vitro (McAllister et al., 2008). Memantine may act directly on 
dopamine D2High receptors (Seeman et al., 2008), whereas amantadine may stimulate the 
synthesis and release of dopamine in the rat striatum (Spilker & Dhasmana, 1973), which is 
beneficial in the treatment of Parkinson’s disease. Aminoadamantane derivatives 4-(1-
adamantylamino)-2,2,6,6-tetramethylpiperidine-1-oxyl and 4-(1-adamantylammonio)-1-
hydroxy-2,2,6,6-tetramethylpiperidinium dihydrochloride were also synthesised as 
antiparkinsonian drugs (Skolimowski et al., 2003). However, compounds with adamantane 
moieties attached to the DHP structure have not yet been synthesised. 
In this study, we tested novel compounds in vitro to assess their influence on mitochondrial 
processes in primary cultures of rat cortical neurons, using mitochondrial toxin MPP+, and 
on isolated rat liver mitochondria. 
2. Materials and methods 
2.1 Animals 
Male Wistar rats (250-350 g), housed at 22 ± 2 ºC under artificial light for a 12-h light/dark 
cycle and with access to water and food ad libitum, were used for these experiments. All of 
the experimental procedures were performed in accordance with the guidelines of Directive 
86/609/EEC “European Convention for the Protection of Vertebrate Animals Used for 
Experimental and Other Scientific Purposes” (1986) and were approved by the National 
Ethics Committee. 
2.2 Chemicals 
AV-6-93 [2,6- dimethyl-3-(1-adamantyloxycarbonyl)-4-(2-difluoromethoxyphenyl)-5-[(2-
propoxy)ethoxycarbonyl]-1,4-dihydropyridine] (Fig. 1A) and diflurone [2,6- dimethyl-3,5-
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bis(1-adamantyloxycarbonyl)-4-(2-difluoromethoxyphenyl)-1,4-dihydropyridine] (Fig. 1B) 
were synthesised at the Latvian Institute of Organic Synthesis, 21 Aizkraukles Street, Riga, 
LV-1006.  AV-6-93 and diflurone were dissolved in 100% DMSO and further diluted to 
concentrations of 0.1% (v/v) and less. 
Chemicals for the mitochondrial studies were obtained from Sigma Chemical Company (St 
Louis, MO, USA); chemicals for cytotoxicity studies mentioned in 2.3. and 2.4. 
 
 
Fig. 1. The structures of AV-6-93 (A) and diflurone (B). 
2.3 Primary culture of rat cortical neurons 
Primary cultures were prepared from 1-day-old Wistar rat pups, according to the method of 
Alho et al., 1988, with minor modifications. Briefly, cortices were dissected in ice-cold Krebs-
Ringer solution (135 mM NaCl, 5 mM KCl, 1 mM MgSO4, 0.4 mM KH2PO4, 15 mM glucose, 
20 mM HEPES, pH 7.4, containing 0.3% bovine serum albumin) and trypsinised in 0.8% 
trypsin-EDTA (Invitrogen, U.K.) for 10 min at 37 °C, followed by trituration in 0.008% 
DNAse I solution containing 0.05% soybean trypsin inhibitor (both obtained from Surgitech 
AS, Estonia). Cells were resuspended in Eagle’s basal medium with Earle’s salts (BME, 
Invitrogen, U.K.), containing 10% heat-inactivated foetal bovine serum (FBS, Invitrogen, 
U.K.), 25 mM KCl, 2 mM GlutaMAXTM-I (Invitrogen, U.K.) and 100 g/mL gentamycin. 
Cells were plated onto poly-L-lysine- (Sigma Chemical Co., MO, USA) coated 48-well plates 
at a density of 1.8 x 105 cells/cm2. The medium was changed to NeurobasalTM-A medium 
containing 2 mM GlutaMAXTM-I with B-27 supplement and 100 μg/mL gentamycin 2.5 hr 
later. Cultures were incubated for 6 days in a 5% CO2/95% air atmosphere at 37 C, and 
one-fifth of the culture medium was changed on DIV 3 (day 3 in vitro). 
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2.4 Measurement of cell death in cytotoxicity assay 
Primary rat cortical neurons were cultured for 5 days as described above. On DIV 5, cultures 
were incubated with 1-methyl, 4-phenylpyridinium (MPP+, Sigma Chemical Co., MO, USA) 
for the following 24 hr at a concentration of 300 μM. Cells were pre-incubated with the 
tested compounds AV-6-93 and diflurone for 90 min followed by the addition of MPP+ and 
further incubation with MPP+ plus the tested compounds or a solvent (control) for the next 
24 hours. Cell death was measured with a Trypan blue assay (Tymianski et al., 1993). Cells 
were incubated with 0.4% Trypan blue solution in phosphate buffered saline (PBS, 145 mM 
NaCl, 3 mM KCl, 0.42 mM Na2HPO4, 2.4 mM KH2PO4, pH = 7.4) at 37 ºC for 7 min and then 
washed twice with PBS and fixed with 4% paraformaldehyde in PBS. Only dead neurons 
were stained with Trypan blue (Tymianski et al., 1993). The fixed cultures were rinsed with 
PBS for microscopic observation, and approximately 150 cells per 5 fields in each well were 
counted to determine the number of dead cells and the total number of cells. Neuronal 
death was calculated as the percentage of dead cells from the total (viable plus dead) 
number of cells, and the obtained data were averaged for each well. 
2.5 Isolation of rat liver mitochondria 
Rat liver mitochondria were isolated from male Wistar rats by differential centrifugation 
according to conventional methods (Gazotti et al., 1979). After washing, the pellet was 
gently resuspended in the washing medium at a protein concentration of about 50 mg/ml. 
Protein content was determined by the biuret method (Gornall et al., 1949), using bovine 
serum albumin as a standard. 
2.6 Measurement of respiratory activities 
Oxygen consumption was monitored polarographically with a Clark-type electrode at 30 °C 
in a closed glass chamber equipped with magnetic stirring. Mitochondria (1 mg/ml) were 
incubated in a respiratory medium containing 130 mM sucrose, 5 mM HEPES (pH 7.2), 50 
mM KCl, 2.5 mM K2HPO4, and 2.5 mM MgCl2 (in the presence and absence of AV-6-93 or 
diflurone) for 3 min before energisation with 10 mM glutamate/5 mM malate. When 10 mM 
succinate was used as the respiratory substrate, the reaction medium was supplemented 
with 2 µM rotenone. To induce state 3 respiration, adenosine diphosphate (ADP, 150 µM) 
was added. FCCP (p-trifluoromethoxyphenylhydrazone)-stimulated respiration was 
initiated by the addition of 1µM FCCP. The respiratory control ratio (RCR), which is 
calculated by the ratio between state 3 (consumption of oxygen in the presence of substrate 
and ADP) and state 4 (consumption of oxygen after ADP phosphorylation), is an indicator 
of mitochondrial membrane integrity. The ADP/O ratio, which is expressed by the ratio 
between the amounts of ADP added and the oxygen consumed during state 3 respiration, is 
an index of oxidative phosphorylation efficiency. Respiration rates were calculated 
assuming that the saturation of oxygen concentration was 250 µM at 30 ºC (Chance & 
Williams, 1956), and the values are expressed in percentage of control (% of control). 
2.7 Measurement of mitochondrial transmembrane potential 
The mitochondrial transmembrane potential (∆) was measured indirectly based on the 
detection of lipophilic cation tetraphenylphosphonium (TPP+) using a TPP+-selective 
electrode, as previously described (Kamo et al., 1979). The ∆ was estimated from the 
following equation (1): 
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 ∆ = 59 x log (v/V) – 59 x log (10∆E/59 – 1) (1) 
where v, V, and ∆E stand for inner mitochondrial volume, incubation medium volume, and 
deflection of the electrode potential from the baseline, respectively. A mitochondrial matrix 
volume of 1.1 µl/mg protein was assumed. No correction was made for the “passive” 
binding of TPP+ to the mitochondrial membranes because the purpose of the experiments 
was to show relative changes in potential rather than absolute values. As a consequence, we 
anticipate some overestimation for the ∆ values. To monitor ∆ associated with 
mitochondrial respiration, liver mitochondria (1 mg/ml) were incubated for 3 min in the 
respiratory medium described above, supplemented with 3 M TPP+, at 30 °C in the absence 
or presence of different concentrations of AV-6-93 or diflurone before energisation with 10 
mM glutamate/5 mM malate or 10 mM succinate. When succinate was used as the 
respiratory substrate, the medium was supplemented with 2 µM rotenone. AV-6-93 or 
diflurone did not affect TPP+ binding to mitochondrial membranes or the electrode 
response. 
2.8 Ca
2+
-induced mitochondrial membrane transition pore (MPT) 
Ca2+-induced MPT was evaluated by measuring changes in mitochondrial transmembrane 
potential (∆) using a TPP+ electrode, changes in oxygen consumption using a Clark-type 
electrode, and changes in Ca2+ fluxes using a Ca2+-selective electrode. The reactions were 
conducted in a medium containing 200 mM sucrose, 10 mM Mops-Tris (pH 7.4), 1 mM 
KH2PO4, and 10 µM EGTA, supplemented with 2 µM rotenone, as previously described 
(Custódio et al., 1998a, 1998b). Mitochondria (1mg/ml) that were incubated at 30 °C for 3 
min (in the absence and presence of AV-6-93 or diflurone) were energised with 10 mM 
succinate, and the single addition of Ca2+ (100 nmol/mg protein) was used to induce MPT. 
Control assays, in both the absence and presence of Ca2+ plus 0.75 nmol/mg protein 
cyclosporin A (CsA) and compound (when necessary) were also performed. 
2.9 Lipid peroxidation 
The extent of lipid peroxidation was evaluated by oxygen consumption using a Clark-type 
electrode at 30 ºC in an open glass chamber equipped with magnetic stirring. Mitochondria 
(1 mg/ml) were pre-incubated for 3 min in a medium containing 175 mM KCl, 10 mM Tris–
Cl (pH 7.4), supplemented with 3 µM rotenone (in the presence or absence of tested 
compounds) to avoid mitochondrial respiration induced by endogenous respiratory 
substrates. The iron solution was prepared immediately before use and was protected from 
light. The changes in O2 tension were recorded in a potentiometric chart record and oxygen 
consumption was calculated assuming an oxygen concentration of 230 nmol/ml. Membrane 
lipid peroxidation was initiated by adding 1 mM ADP/0.1 mM Fe2+ as oxidizing agents. 
Controls, in the absence of ADP/Fe2+, were performed under the same conditions. 
Lipid peroxidation was also determined by measuring thiobarbituric acid reactive 
substances (TBARs), using the thiobarbituric acid assay (Ernster & Nordenbrand, 1967). 
Aliquots of mitochondrial suspensions (0.5 ml each), removed 10 min after the addition of 
ADP/Fe2+, were added to 0.5 ml of ice cold 40% trichloroacetic acid. Then, 2 ml of 0.67% of 
aqueous thiobarbituric acid containing 0.01% of 2,6-di-tert-butyl-p-cresol was added. The 
mixtures were heated at 90 °C for 15 min, then cooled on ice for 10 min, and centrifuged at 
850 g for 10 min. Controls, in the absence of ADP/Fe2+, were performed under the same 
conditions. The supernatant fractions were collected and lipid peroxidation was estimated 
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spectrophotometrically at 530 nm. As blanks, we used control reactions performed in the 
absence of mitochondria and ADP/Fe2+. The amount of TBARs formed was calculated using 
a molar extinction coefficient of 1.56 x 105 mol-1 cm-1 and expressed as nmol TBARs/mg 
protein (Buege & Aust, 1978). 
2.10 Statistical analysis 
The cytotoxicity data were calculated as a mean ± S.E. Statistical analysis was performed 
using Student’s t-test or one-way analysis of variance (ANOVA), followed by a Bonferroni 
multiple comparisons test. 
The mitochondrial experiments were performed using three independent experiments with 
different mitochondrial preparations. The values are expressed as means ± S.E. Means were 
compared using one-way ANOVA for multiple comparisons, followed by Tukey’s test. 
Statistical significance was set at p< 0.05. 
3. Results 
3.1 Protection against the cell death induced by MPP
+
 
In primary rat cortical neurones, AV-6-93 at concentrations of 1 and 10 µM decreased MPP+-
induced cell death by 75% and 56%, respectively (Fig. 2A). Diflurone exerted the protective 
ability only at the highest tested concentration, 10 μM, and decreased the MPP+-induced cell 
death by 35% (Fig. 2B). Neither AV-6-93 nor diflurone, added without MPP+, changed cell 
viability at the highest tested concentrations (Fig. 2). 
3.2 Effects of AV-6-93 and diflurone on rat liver mitochondrial bioenergetics 
AV-6-93 and diflurone (up to 100 μM) were studied for their effects on mitochondrial 
bioenergetics by evaluating several mitochondrial respiratory chain parameters (state 2, 
state 3, state 4, FCCP-stimulated respiration, RCR, ADP/O ratio, ∆, and phosphorylation 
rate) using glutamate/malate as the respiratory substrate. 
The effects of AV-6-93 on glutamate/malate-supported respiratory rates (state 2, state 3, 
state 4 and FCCP-stimulated respiration), respiratory indices RCR and ADP/O of rat liver 
mitochondria were almost non-existent and insignificant at concentrations of up to 100 µM 
(Table 1), indicating that the compounds did not significantly affect mitochondrial 
bioenergetics. 
These results are demonstrated in Table 2, where AV-6-93 and diflurone, at concentrations 
of up to 100 µM, did not significantly affect either the ∆ induced by glutamate/malate-
dependent respiration or the phosphorylation time. 
As for glutamate/malate-supported respiration, the effects of AV-6-93 and diflurone on 
succinate-supported respiratory rates (state 2, state 3, state 4 and FCCP) and respiratory 
indices RCR and ADP/O of rat liver mitochondria were not significantly affected (results 
not shown), further supporting the finding that these compounds did not affect 
mitochondrial bioenergetics. 
3.3 Effects of AV-6-93 and diflurone on Ca
2+
-induced MPT 
The effect of AV-6-93 and diflurone on Ca2+-induced MPT was studied in order to evaluate 
their capacity to protect mitochondria against MPT opening by measuring the decrease in 
∆, the increase in oxygen consumption, and the Ca2+-induced release of mitochondrial 
Ca2+, which are typical phenomena that follow the induction of MPT. The amount of Ca2+ 
used to induce MPT was 100 nmol/mg protein. 
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Fig. 2. Influence of AV-6-93 (AV) and diflurone (D) on MPP+-induced cell death in primary 
rat cortical neurons (A and B, respectively). Cell death measured by Trypan blue method. 
Data are presented as a mean  S.E.  p < 0.001 vs control, t-test, *** p < 0.001 vs MPP+, 
one-way ANOVA followed by Bonferroni multiple comparison’s test. 
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Compounds 
(µM) 
Oxygen consumption (% of control) 
RCR ADP/O 
State 2 State 3 State 4 
State 
FCCP 
AV-6-93       
0.0 100.0 ± 0.0 100 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 6.8 ± 1.3 3.01 ± 0.1 
1.0 100.0 ± 0.0 113.4 ± 6.7 94.4 ± 5.6 100.2 ± 8.7 6.5 ± 1.5 2.9 ± 0.1 
10.0 105.0 ± 18.9 104.0 ±7.3 119.4 ± 10.0 101.9 ± 7.3 6.4 ± 1.0 2.8 ± 0.4 
100.0 127.2 ± 31.9 109.9 ± 6.6 145.8 ± 44.5 91.2 ± 8.5 6.3 ± 2.7 2.8 ± 0.1 
Diflurone       
0 100.0± 0.0 100.0± 0.0 100.0± 0.0 100.0± 0.0 6.8 ± 1.3 3.01 ± 0.1 
100 107.3 ± 4.8 95.9 ± 2.9 104.4 ± 5.27 94.4 ± 4.03 6.4 ± 1.2 2.9 ± 0.09 
Table 1. Effects of AV-6-93 and diflurone on the respiratory parameters (state 2, state 3, state 
4, FCCP-stimulated respiration) and respiratory indices (RCR and ADP/O ratio) of rat liver 
mitochondria using glutamate/malate as respiratory substrate. 
The values, which are given in percentage of control (% of control), correspond to the mean 
± S.E. of the respiratory parameters, evaluated in three different mitochondrial preparations, 
at the different indicated situations. Control values are expressed in nmol O2. mg-1 protein 
min-1: state 2 = 7.1 ± 0.7; state 3 = 39.4 ± 4.0; state 4 = 5.62 ± 0.8; FCCP-stimulated respiration 
= 57.14 ± 10.4. 
 
Compounds 
(µM) 
Δ (mV) 
Phosphorylation 
time (s) Glu/Mal 
energisation 
ADP 
depolarisation
Repolarisation
AV-6-93     
0 -220.5 ± 5.1 21.7 ± 2.2 -216.8 ± 2.6 33.0 ± 3.0 
1 -219.0 ± 4.0 21.3 ± 1.9 -217.0 ± 4.3 32.7 ± 2.9 
10 -220.6 ± 4.1 23.5 ± 2.1 -218.7 ± 4.2 32.5 ± 4.5 
100 -216.0 ± 5.6 23.4 ± 1.1 -212.5 ± 4.7 39.0 ± 1.7 
Diflurone     
0 -220.5 ± 5.1 21.7 ± 2.2 -216.8 ± 2.6 33.0 ± 3.0 
100 -218.0 ± 1.7 21.0± 0.3 -216.0 ± 1.4 32.8 ± 2.3 
Table 2. Effects of AV-6-93 and diflurone on glutamate/malate-dependent transmembrane 
potential (∆) and phosphorylation time of rat liver mitochondria. 
The values correspond to the mean ± S.E. of the Δ and the phosphorylation time, evaluated 
in three different mitochondrial preparations, at the different indicated situations. 
The results of the effect of AV-6-93 on MTP protection are depicted in Fig. 3. Under control 
conditions, the addition of 10 mM succinate to mitochondrial suspensions produced a ∆ of 
about -216 mV (negative inside mitochondria) (Fig. 3A), corresponding to respiratory state 4 
(Fig. 3B). The addition of Ca2+ led to a rapid depolarisation (decrease of ∆), followed by a 
partial repolarisation (recover of ∆), the subsequent total depolarisation of mitochondria 
(Fig. 3A), and an increase in respiratory state 4 (Fig. 3B). 
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Fig. 3. Effect of AV-6-93 on rat liver MPT induced by Ca2+. 
Evaluation was performed by measuring succinate-supported transmembrane potential 
(∆) (A), oxygen consumption (B), and mitochondrial Ca2+ fluxes (C). Additions of 100 nmol 
calcium/mg protein (Ca2+) and 10 mM succinate (Suc); additions of AV-6-93 at the 
concentrations of 1, 10, and 100 M (1, 10, 100) are indicated. Assays in the absence of Ca2+  
(-Ca2+); assays in the presence of Ca2+ plus CsA (0.75 nmol/mg protein (CsA); assays in the 
presence of Ca2+ plus CsA + 1M AV-6-93 (CsA+ 1). The traces are representative of assays 
with three different mitochondrial preparations. 
These effects were due to the entry of Ca2+ into the electronegative mitochondrial matrix 
(Fig. 3C), followed by the efflux of H+ for restoring the ∆. Incubation of mitochondria with 
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AV-6-93 concentrations of up to 100 µM for 3 min before energisation with succinate 
prevented total depolarisation of mitochondria (Fig. 3A), the increase in respiratory state 4 
(Fig. 3B), and the release of mitochondrial Ca2+ (Fig. 3C), suggesting that this compound has 
a high ability to protect mitochondria against MPT induction. Incubation of mitochondria 
with 0.75 nmol/mg protein, CsA, a specific inhibitor of MPT (Broekemeier et al., 1989), for 2 
min before energising with succinate, either in the absence or presence of 1 μM AV-6-93, 
completely blocked mitochondrial depolarisation (Fig. 3A), the increase in respiratory state 
4 (Fig. 3B), and the Ca2+-induced release of mitochondrial Ca2+ (Fig. 3C). These data show 
that these effects had been induced by MPT. In contrast to AV-6-93, diflurone, in the same 
concentration range, did not prevent either the depolarisation of mitochondria or the release 
of mitochondrial Ca2+ (results not shown), indicating that this compound did not protect 
mitochondria against MPT.  
3.4 Effects of AV-6-93 and diflurone on mitochondrial oxidative stress 
The effects of AV-6-93 and diflurone on mitochondrial oxidative damage were assessed by 
detecting the mitochondrial membrane lipid peroxidation induced by the pro-oxidant pair 
ADP/Fe2+. Lipid peroxidation was evaluated by measuring oxygen consumption (Fig. 4) 
and TBARs formation (Table 3). In the absence of AV-6-93 and after the addition of the pro-
oxidant pair, it is possible to distinguish two-phase kinetics in oxygen consumption: an 
initial lag phase, characterized by slow oxygen consumption lasting about 2 min, is followed 
by a rapid oxygen consumption phase. The lag phase is probably related with the time 
required for the generation of a sufficient amount of the perferryl ion complex (ADP-Fe2+- 
O2  ADP-Fe3+-O2-), which has been suggested to be responsible for the initiation of lipid 
peroxidation. The rapid oxygen consumption phase is probably due to the oxidation of the 
polyunsaturated fatty acid acyl chain of membrane phospholipids by reactive oxygen 
species (ROS) and, consequently, due to the propagation phase of lipid peroxidation (Sassa 
et al., 1990). AV-6-93 concentrations up to 100 M enlarged the lag phase of slow oxygen 
consumption before the oxygen uptake burst induced by the ADP/Fe2+ complex and 
increased the rate of the rapid oxygen consumption phase (Fig. 4), suggesting that the 
compounds affected both the initiation and the propagation of lipid peroxidation of 
mitochondrial membranes. 
These results agree with the quantitative evaluation of TBARs formation performed to 
confirm the protective effects of AV-6-93. The data in Table 3 show that the kinetics of 
TBARs formation induced by ADP/Fe2+ are similar to that observed for oxygen 
consumption. The same range of AV-6-93 concentrations used in the oxygen consumption 
assays also affected TBARs formation. TBARs formation in the absence of ADP/Fe2+ was 
negligible (0.44 ± 0.25 nmol/mg of protein). In contrast to AV-6-93, diflurone, in the same 
concentration range, did not affect oxygen consumption induced by the ADP/Fe2+ complex 
or TBARs formation (results not shown), indicating that this compound has no capacity to 
protect mitochondria against the lipid peroxidation induced by the pro-oxidant pair 
ADP/Fe2+. 
Lipid peroxidation was evaluated by oxygen consumption and initiated by adding 1 mM 
ADP/0.1 mM Fe2+ to mitochondrial suspensions (Fig. 4). The traces represent typical direct 
oxygen consumption recordings of three experiments obtained from different mitochondrial 
preparations; controls in the absence of ADP/Fe2+ (–ADP/Fe2+); assays in the presence of 
AV-6-93 at the concentrations 1, 10, 20, 50, 100 μM (1, 10, 20, 50, 100). 
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Fig. 4. Effect of AV-6-93 on membrane lipid peroxidation of rat liver mitochondria induced 
by the pro-oxidant pair ADP/Fe2+ evaluated by oxygen consumption. 
 
AV-6-93 
(M) 
TBARs 
(nmol/mg protein/10 min) 
0 10.2 ± 1.0 
1 9.6 ± 1.0 
10 8.5 ± 0.5 
20 7.6  ± 1.0 
50 5.2 ± 2.1 
100 3.1± 1.9* 
Table 3. Effect of AV-6-93 on membrane lipid peroxidation of rat liver mitochondria induced 
by the pro-oxidant pair ADP/Fe2+ evaluated by TBARs assay. The data correspond to the 
mean ± S.E. of three independent experiments. 
*p< 0.05 vs control (in the absence of AV-6-93). 
4. Discussion 
Studies examining the importance of mitochondrial pathophysiology in neurodegeneration 
provide a target for additional treatments with agents that improve mitochondrial function, 
protect MPT, and/or exert antioxidant activity (Petrozzi et al., 2007). These studies lead to 
novel approaches in the treatment of neurodegenerative diseases, such as Parkinson’s 
disease, with disease-modifying drugs. 
The aim of the present study was to examine the abilities of two novel adamantane-
containing DHP analogues, AV-6-93 and diflurone, to protect against cell death induced by 
mitochondrial toxin MPP+ and beneficially influence mitochondrial processes in an attempt 
to identify putative antiparkinsonian drugs. 
First, we examined how both compounds acted in primary cortical cultures in response to 
MPP+. AV-6-93, at concentrations of 1 and 10 µM, significantly protected against MPP+-
induced cell death by 75% and 56%, respectively, whereas diflurone protected against cell 
death by 35% at a concentration of 10 µM. Neither AV-6-93 nor diflurone, added without 
MPP+, changed cell viability. 
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A larger difference between the compounds’ activities was observed in isolated rat liver 
mitochondria by the assessment of their ability to affect both the Ca2+-induced 
mitochondrial permeability transition (MPT) and lipid peroxidation. To assess the Ca2+- 
induced MPT, the evaluation of the drop of ∆, the increase in mitochondrial respiration 
associated with Ca2+ accumulation in the mitochondrial matrix, and the mitochondrial Ca2+ 
fluxes were carried out. Changes in these parameters help us to conclude whether the 
compound protects mitochondria against MPT induction and, consequently, to discern 
whether the compound alters mitochondrial Ca2+ homeostasis. AV-6-93, at a concentration 
of 10 µM, significantly protected mitochondria against MTP induction and provided 
complete protection at 100 µM, as revealed by its ability to prevent the depolarisation of 
mitochondria, the increase in mitochondrial respiration and mitochondrial Ca2+ release. 
These effects were comparable with that of CsA (0.75 nmol/mg protein), a specific inhibitor 
of the mitochondrial permeability transition pore. Diflurone was ineffective in these tests. 
The effectiveness of AV-6-93 can be considered to be very promising because it indicates the 
ability of this compound to halt mitochondrial swelling and cell death, both consequences of 
the induction of the permeability transition pore. 
A critical factor for induction of MPT is the oxidation of thiol groups of the MPT complex, 
creating diethyl cross-links (Costantini et al., 1996; 1998, Halestrap et al., 1997; McStay et al., 
2002). Therefore, the most plausible hypothesis to explain the partial MPT protection 
induced by AV-6-93 is that changes in the redox-state of thiol groups of the MPT complex is 
provided via avoiding of diethyl cross-links. This hypothesis is supported by the 
observation that AV-6-93 protected mitochondria against oxidative stress. Oxidative stress 
was assessed by evaluating the extent of lipid peroxidation by measuring oxygen 
consumption and TBARs formation. Alterations of these parameters may reveal whether the 
compound protects mitochondria against oxidative stress, i.e., whether the compound acts 
as an antioxidant. AV-6-93, at concentrations up to 100 µM, protected (by about a half) 
mitochondria against membrane lipid peroxidation, as inferred by its ability to inhibit both 
oxygen consumption and TBARs formation induced by the pro-oxidant pair ADP/Fe2+. 
These data suggest that this compound may act as antioxidant because it can avoid both the 
initiation and the propagation of the oxidation of polyunsaturated fatty acid acyl chains of 
membrane phospholipids induced by the perferryl ion complex ADP-Fe3+-O2-, a mechanism 
suggested to be responsible for lipid peroxidation (Sassa et al., 1990). In contrast to AV-6-93, 
diflurone, under the same conditions, had no capacity to protect mitochondria against 
oxidative damage induced by the pro-oxidant pair ADP/Fe2+. 
The only common feature of both compounds was a lack of influence on mitochondrial 
bioenergetics, which was assessed by analysing several mitochondrial functioning 
parameters of the respiratory chain (respiration states 2, 3, 4, FCCP-stimulated respiration, 
the RCR, and the ADP/O ratio) and the oxidative phosphorylation system (∆ and 
phosphorylation time), using both glutamate/malate and succinate as respiratory 
substrates. According to the mitochondrial parameters affected, it is possible to assess how 
the compound interferes with mitochondrial bioenergetics: by perturbing the permeability 
(integrity) of the inner mitochondrial membrane (stimulation of respiration states 2 and 4), 
by impairing the respiratory chain (inhibition of FCCP-stimulated respiration), and/or by 
acting at the level of the phosphorylation system (affecting respiration state 3). Both AV-6-93 
and diflurone, at concentrations of up to 100 µM, failed to significantly affect liver 
mitochondrial bioenergetics, as shown by the lack of effects on both glutamate/malate- and 
succinate-supported respiration in state 2, state 3, state 4, FCCP-stimulated respiration, RCR 
and ADP/O ratios, ∆ and phosphorylation time. 
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To address why both adamantane-containing compounds showed very distinct effects on 
mitochondrial damage induced by both Ca2+ and ADP/Fe2+, one may suggest that the 
molecular “volume” of AV-6-93 (one adamantane ring-containing DHP) is more optimal 
than that of diflurone (two adamantane ring-containing DHP) for mitochondrial protection. 
The two adamantane rings in the diflurone molecule probably generate a steric hindrance 
that prevents or delays the chemical reaction, which can easily occur in the case of AV-6-93, 
a one adamantine ring-containing DHP. 
Based on the results obtained in primary cortical cultures, the two-adamantane DHP 
structure is not as crucial as it is in isolated rat liver mitochondria because diflurone has not 
lost its activity to prevent cell death caused by MPP+ (a toxin focused on mitochondrial 
complex I). However, the activity of diflurone was lower than that of AV-6-93. One could 
suggest that, in addition to the protection of complex I, other cellular signalling mechanisms 
may be initiated by DHP compounds to increase cell survival. 
5. Conclusion 
The novel one-adamantane 1,4-dihydropyridine compound AV-6-93 is capable of regulating 
cell survival processes with regards to mitochondrial processes, such as inhibition of the 
induction of the permeability transition pore and prevention of oxidative stress. The 
effectiveness of AV-6-93 can be considered to be very promising in the treatment of 
neurodegenerative diseases associated with compromised mitochondrial processes, e.g., 
Parkinson’s disease. 
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